Ofelia A. Olivero, Ph.D.
Ofelia A. Olivero, Ph.D.
Associate Scientist

Dr. Olivero has pioneered the elucidation of the genotoxicity induced in pregnant women by drugs taken to prevent HIV-1 vertical transmission. The health of women during pregnancy and the wellbeing of the newborn have been her focus and concern in the quest to understand the latent toxicities that can develop into disease later in life. Her contributions helped shape the observation that AZT and other nucleoside reverse transcriptase inhibitors were responsible for DNA damage in utero and later induction of tumorigenesis in rodents.

Areas of Expertise
transplacental carcinogenesis, genotoxicity, nucleoside analogs, carcinogenesis

Contact Info

Ofelia A. Olivero, Ph.D.
Center for Cancer Research
National Cancer Institute
Building 37, Room 4032B
Bethesda, MD 20892
301-435-7843
oliveroo@exchange.nih.gov

Transplacental Carcinogenesis. Nucleoside analogs induced carcinogenesis. Centrosomal amplification and aneuploidy.

Selected Publications
  1. Olivero OA.
    Environ. Mol. Mutagen.. 48: 215-23, 2007. [ Journal Article ]
  2. Olivero OA, Torres LR, Gorjifard S, Momot D, Marrogi E, Divi RL, Liu Y, Woodward RA, Sowers MJ, Poirier MC.
    J. Infect. Dis.. 208: 244-8, 2013. [ Journal Article ]
  3. Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, Jones AB, Rice JM, Riggs CW, Logsdon D, Yuspa SH, Poirier MC.
    J. Natl. Cancer Inst.. 89: 1602-8, 1997. [ Journal Article ]
  4. Olivero OA, Shearer GM, Chougnet CA, Kovacs AA, Landay AL, Baker R, Stek AM, Khoury MM, Proia LA, Kessler HA, Sha BE, Tarone RE, Poirier MC.
    AIDS. 13: 919-25, 1999. [ Journal Article ]
  5. Olivero OA, Tejera AM, Fernandez JJ, Taylor BJ, Das S, Divi RL, Poirier MC.
    Mutagenesis. 20: 139-46, 2005. [ Journal Article ]

Dr. Ofelia A. Olivero obtained her PhD in cytogenetics in Argentina and subsequently joined the National Cancer Institute where she has worked since 1987. Dr. Olivero's initial work focused on the relationship between cytogenetics and cancer, and she was able to map DNA adducts on chromosomes using antibodies against DNA adducts. Later she focused on transplacental carcinogenesis induced by the nucleoside analogs that are mainly used in AIDS therapy. Together with her colleagues, she showed for the first time that the nucleoside analog used in the earliest AIDS therapy was a transplacental carcinogen in mice. She is currently a Senior Staff Scientist in the Laboratory of Cancer Biology and Genetics at NCI where she is applying molecular techniques to investigate mechanisms of nucleoside analog-induced carcinogenesis and exploring centrosomal amplification induced by nucleoside analogs. She has been instrumental in the creation and organization of the Staff Scientists/Staff Clinicians Organization in CCR, NCI, and is a past Co-chair for that organization. She is a past Chair of the Executive Board of the Genetic Toxicology Association and Vice President of the Environmental Mutagenesis and Genomics Society. Her mentoring abilities and dedication to minorities under-represented in sciences is reflected on the numerous leadership positions she holds in scientific societies. She is Co-chair of the Committee on Diversity Initiatives of the Society of Toxicology as well as a Past President of the Hispanic Organization for Toxicology. Dr. Olivero has been an active member of the NIH-Hispanic Employee Organization since 1999 and is currently a past president. She is a member of the Minorities in Cancer Research group as well as Women in Cancer Research, Women in Toxicology and Women in EMGS. She has been invited to mentor students and to participate in SACNAS, Society for the Advance of Chicanos and Native Americans in Science. She is the author of more than 70 peer-reviewed articles and has been invited to deliver numerous talks in the USA and abroad. She is the recipient of many awards, including the Leading Diversity Award form the National Cancer Institute. She has recently been recognized as a Fellow by the Academy of Toxicological Sciencies (ATS).

Research

Transplacental Carcinogenesis. Nucleoside analogs induced carcinogenesis. Centrosomal amplification and aneuploidy.

Publications

Selected Publications
  1. Olivero OA.
    Environ. Mol. Mutagen.. 48: 215-23, 2007. [ Journal Article ]
  2. Olivero OA, Torres LR, Gorjifard S, Momot D, Marrogi E, Divi RL, Liu Y, Woodward RA, Sowers MJ, Poirier MC.
    J. Infect. Dis.. 208: 244-8, 2013. [ Journal Article ]
  3. Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, Jones AB, Rice JM, Riggs CW, Logsdon D, Yuspa SH, Poirier MC.
    J. Natl. Cancer Inst.. 89: 1602-8, 1997. [ Journal Article ]
  4. Olivero OA, Shearer GM, Chougnet CA, Kovacs AA, Landay AL, Baker R, Stek AM, Khoury MM, Proia LA, Kessler HA, Sha BE, Tarone RE, Poirier MC.
    AIDS. 13: 919-25, 1999. [ Journal Article ]
  5. Olivero OA, Tejera AM, Fernandez JJ, Taylor BJ, Das S, Divi RL, Poirier MC.
    Mutagenesis. 20: 139-46, 2005. [ Journal Article ]

Biography

Dr. Ofelia A. Olivero obtained her PhD in cytogenetics in Argentina and subsequently joined the National Cancer Institute where she has worked since 1987. Dr. Olivero's initial work focused on the relationship between cytogenetics and cancer, and she was able to map DNA adducts on chromosomes using antibodies against DNA adducts. Later she focused on transplacental carcinogenesis induced by the nucleoside analogs that are mainly used in AIDS therapy. Together with her colleagues, she showed for the first time that the nucleoside analog used in the earliest AIDS therapy was a transplacental carcinogen in mice. She is currently a Senior Staff Scientist in the Laboratory of Cancer Biology and Genetics at NCI where she is applying molecular techniques to investigate mechanisms of nucleoside analog-induced carcinogenesis and exploring centrosomal amplification induced by nucleoside analogs. She has been instrumental in the creation and organization of the Staff Scientists/Staff Clinicians Organization in CCR, NCI, and is a past Co-chair for that organization. She is a past Chair of the Executive Board of the Genetic Toxicology Association and Vice President of the Environmental Mutagenesis and Genomics Society. Her mentoring abilities and dedication to minorities under-represented in sciences is reflected on the numerous leadership positions she holds in scientific societies. She is Co-chair of the Committee on Diversity Initiatives of the Society of Toxicology as well as a Past President of the Hispanic Organization for Toxicology. Dr. Olivero has been an active member of the NIH-Hispanic Employee Organization since 1999 and is currently a past president. She is a member of the Minorities in Cancer Research group as well as Women in Cancer Research, Women in Toxicology and Women in EMGS. She has been invited to mentor students and to participate in SACNAS, Society for the Advance of Chicanos and Native Americans in Science. She is the author of more than 70 peer-reviewed articles and has been invited to deliver numerous talks in the USA and abroad. She is the recipient of many awards, including the Leading Diversity Award form the National Cancer Institute. She has recently been recognized as a Fellow by the Academy of Toxicological Sciencies (ATS).